FDA pauses Mersana’s clinical trial after patient dies
The FDA has paused Mersana Therapeutics’ Phase I clinical trial for a cancer treatment after a patient died, the biotech said Monday morning.
The death was deemed to be related to its drug, the Cambridge, MA-based biotech said.
The patient who died was the second to be dosed in Mersana’s clinical trial for a STING agonist — a drug target that scientists believe can boost immune response against tumors but has seen a number of challenges over the years, from low efficacy to nixed programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.